Full Press Release Details
T2 Biosystems Announces First Quarter 2023 Financial Results
Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives
LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the rapid detection of
sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the first quarter ended March 31, 2023.
Financial and Operational Highlights
Recent Pipeline and Clinical Highlights
In an effort to maximize value, we have engaged an advisory firm to explore all
potential strategic alternatives. In addition, to preserve capital, decrease quarterly cash usage and position the Company to explore strategic alternatives, we have simultaneously implemented a restructuring program, stated John Sperzel,
Chairman and CEO of T2 Biosystems. In the first half of the year, we have made very important advances in our product pipeline, including FDA 510(k) submission for the T2Biothreat Panel, FDA Breakthrough Device Designation application for
Candida auris, completion of assay development for the T2Lyme Panel, and completed nearly 90% of patient enrollment in the T2Resistance Panel U.S. clinical trial, which position us to expand our addressable markets in the future.
First Quarter 2023 Financial Results
the first quarter of 2023 was $2.1 million, a 71% decrease compared to the prior year period, driven by a decline in COVID-19 test sales and reduced BARDA activities. Product revenue was
$1.7 million, a decrease of 57% compared to the prior year period, driven by the expected 98% decline in COVID-19 test sales and partially offset by increased sepsis test sales. Research contribution
revenues were $0.4 million, an 88% decrease compared to the prior year period, driven by the level of BARDA contract activities.
Cost of product revenue for the first quarter of 2023 was $4.0 million, a 35% decrease compared to the
prior year period, driven by decreased COVID-19 test sales. Research and development expenses were $4.5 million, a 33% decrease compared to the prior year period, driven by decreased BARDA contract
activities. Selling, general and administrative expenses were $7.3 million, a 21% decrease compared to the prior year period driven by decreased Medical Affairs spending.
Net loss for the first quarter of 2023 was $18.0 million, $1.32 per share, compared to a net loss of $16.5 million, $4.86 per share, in the prior
Cash and cash equivalents totaled $10.1 million as of March 31, 2023. The Company raised $1.0 million in net proceeds through
ATM sales in the first quarter of 2023 and in February 2023, raised $11.0 million, net through a common stock and warrants sale. The impact of the incremental 30% workforce reduction is expected to significantly decrease cash usage in the
subsequent quarters.
2023 Financial Outlook
Company reiterates its full year 2023 financial outlook and continues to expect total sepsis and related product revenue of $11.0 million to $13.0 million, representing growth of 31% to 55%, compared to $8.4 million in 2022. Given the
focus on product revenue, the Company is not providing guidance on research and contribution revenue.
Webcast and Conference Call Information
The Company s management team will host a conference call today, May 23, 2023, beginning at 8:30 am ET. Investors interested in listening to the call
may do so by dialing 877-545-0523 for domestic callers or 973-528-0016 for International
callers and using conference ID 717782 approximately five minutes prior to the start time. A live and recorded webcast of the call will be available on the Investors section of the Company s website at www.t2biosystems.com.
T2 Biosystems, a leader in the
rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems products
include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the
T2Resistance Panel, and the T2SARS-CoV-2 Panel and
are powered by the proprietary T2 Magnetic Resonance (T2MR ) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat Panel, the T2Cauris Panel, and T2Lyme Panel, as well as next-generation
products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements,
including, without limitation, statements regarding our revenue results and cash balance, financial outlook, instrument contracts, timing of completing clinical trials and filing of an FDA submission, impact of operating expense reductions,
anticipated strategic priorities, product demand, commitments or opportunities, and growth expectations or targets, as well as statements that include the words expect, may, should, anticipate, and
similar statements of a future or forward looking nature. These forward-looking statements are based on management s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties
and other important factors that may cause actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to,
(i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption;
(e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer
facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. Risk
Factors in the Company s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2023, and other
filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors
could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management s estimates as of the date of this press release. While
the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the
Company s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company s views as of any date
subsequent to the date of this press release.
Philip Trip Taylor, Gilmartin Group
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| March 31, 2023 | December 31, 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 10,117 | $ | 10,329 | ||||
| Accounts receivable | 1,323 | 2,163 | ||||||
| Inventories | 4,936 | 4,285 | ||||||
| Prepaid expenses and other current assets | 2,549 | 2,582 | ||||||
| Total current assets | 18,925 | 19,359 | ||||||
| Property and equipment, net | 4,801 | 4,533 | ||||||
| Operating lease right-of-use assets | 8,420 | 8,741 | ||||||
| Restricted cash | 551 | 1,551 | ||||||
| Other assets | 35 | 143 | ||||||
| Total assets | $ | 32,732 | $ | 34,327 | ||||
| Liabilities and stockholders deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,131 | $ | 1,296 | ||||
| Accrued expenses and other current liabilities | 5,162 | 7,269 | ||||||
| Operating lease liability | 1,415 | 1,352 | ||||||
| Warrant liabilities | 7,972 | 39 | ||||||
| Deferred revenue | 149 | 172 | ||||||
| Total current liabilities | 17,829 | 10,128 | ||||||
| Notes payable | 50,108 | 49,651 | ||||||
| Operating lease liabilities, net of current portion | 7,832 | 8,214 | ||||||
| Deferred revenue, net of current portion | 74 | 52 | ||||||
| Derivative liability related to Term Loan | 1,858 | 1,088 | ||||||
| Accrued interest on term loan | 4,917 | 4,849 | ||||||
| Total liabilities | 82,618 | 73,982 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders deficit | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | ||||||||
| Common stock, $0.001 par value; 400,000,000 shares authorized; 20,368,463 and 7,716,519 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 21 | 8 | ||||||
| Additional paid-in capital | 502,277 | 494,556 | ||||||
| Accumulated deficit | (552,184 | ) | (534,219 | ) | ||||
| Total stockholders deficit | (49,886 | ) | (39,655 | ) | ||||
| Total liabilities and stockholders deficit | $ | 32,732 | $ | 34,327 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 1,655 | $ | 3,844 | ||||
| Contribution revenue | 423 | 3,390 | ||||||
| Total revenue | 2,078 | 7,234 | ||||||
| Costs and expenses: | ||||||||
| Cost of product revenue | 3,995 | 6,205 | ||||||
| Research and development | 4,471 | 6,656 | ||||||
| Selling, general and administrative | 7,299 | 9,230 | ||||||
| Total costs and expenses | 15,765 | 22,091 | ||||||
| Loss from operations | (13,687 | ) | (14,857 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 2 | 3 | ||||||
| Interest expense | (1,522 | ) | (1,650 | ) | ||||
| Change in fair value of derivative related to Term Loan | (770 | ) | ||||||
| Change in fair value of warrant liabilities | (1,304 | ) | ||||||
| Other income | 11 | |||||||
| Other expense | (682 | ) | ||||||
| Other losses | (2 | ) | (2 | ) | ||||
| Total other expense | (4,278 | ) | (1,638 | ) | ||||
| Net loss and comprehensive loss | $ | (17,965 | ) | $ | (16,495 | ) | ||
| Net loss per share basic and diluted | $ | (1.32 | ) | $ | (4.86 | ) | ||
| Weighted-average number of common shares used in computing net loss per share basic and diluted | 13,633,352 | 3,397,103 |